RVNC News and Press, Revance Therapeutics Inc. From 02/14/20

Conference Call Scheduled for Monday, February 24, 2020 at 4:30 p.m. ET Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology pioneer focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection ...

Revance Therapeutics (NASDAQ: RVNC ) prices its private $250M (from $200M) offering of 1.75% convertible senior notes due 2027 at par. Initial buyers have a 13-day option to purchase an additional $37.5M of the notes. More news on: Revance Therapeutics, Inc., Healthcare stocks news, Stoc...

Revance Therapeutics, Inc. (“Revance”) (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced the pricing of $250.0 million aggregate principal amount of 1.75% convertible senio...

  Revance Therapeutics, Inc. (“Revance”) (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that it intends to offer, subject to market conditions and other factor...

Shares of  Allergan   (NYSE: AGN) received a slight bump on Monday morning in response to a fourth-quarter earnings report that exceeded expectations on the top and bottom lines. Shares of AbbVie (NYSE: ABBV) , a larger drugmaker with plans to buy Allergan in the first quarter...

Revance Therapeutics (NASDAQ: RVNC), a biotechnology pioneer focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection (“DAXI”), today announced the U.S. Food and Drug Administration’s...

A new alternative to Allergan 's (NYSE: AGN) blockbuster aesthetics treatment Botox may be available by the end of 2020. On Thursday,  Revance Therapeutics (NASDAQ: RVNC)  announced the Food and Drug Administration (FDA) accepted its application for approval of DAXI (daxibotulinum...

Revance Therapeutics (NASDAQ: RVNC ) has filed a marketing application in the U.S. seeking approval of DAXI (daxibotulinumtoxinA for injection) for the treatment of moderate-to-severe glabellar (frown) lines. The agency's action date is November 25. More news on: Revance Therapeutics, In...

- Prescription Drug User Fee Act (PDUFA) target action date of November 25, 2020 - Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology pioneer focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA f...

The following slide deck was published by Revance Therapeutics, Inc. in conjunction with this Read more ...